1. Nanocarrier vaccine therapeutics for global infectious and chronic diseases
- Author
-
Simnani, Faizan Zarreen, Singh, Dibyangshee, Patel, Paritosh, Choudhury, Anmol, Sinha, Adrija, Nandi, Aditya, Samal, Shailesh Kumar, Verma, Suresh K., Panda, Pritam Kumar, Simnani, Faizan Zarreen, Singh, Dibyangshee, Patel, Paritosh, Choudhury, Anmol, Sinha, Adrija, Nandi, Aditya, Samal, Shailesh Kumar, Verma, Suresh K., and Panda, Pritam Kumar
- Abstract
Immunization has the potential to become a viable weapon for the upcoming pandemic and save millions of lives, while also dramatically lowering the high mortality rate brought on by a number of infectious and chronic illnesses. Despite the success of some vaccinations for infectious illnesses, obstacles remain in avoiding and creating fully protective vaccines. Current COVID-19 pandemic highlights need for vaccination platform improvements. Nanomaterials have been created as a possible nanocarrier to elicit a robust immune response against important global morbidity and mortality drivers by encapsulating targeted antigen and functionalizing nanoparticles with particular molecules. In addition to their application in cancer immunotherapy, nanocarriers are currently being included into the development of vaccines against human immunodeficiency virus (HIV), malaria, TB, and influenza. In order to evaluate conventional and next-generation vaccination platforms, this study focuses on the COVID-19 and cancer vaccine as well as the passage and interaction of nanoparticles with immune cells in the lymph node. It also draws attention to the gaps in current and future HIV, TB, malaria, and influenza vaccinations, as well as nanovaccines. The importance of the dose-dependent vaccine in inducing and maintaining neutralizing antibodies after immunization has been discussed in more detail.
- Published
- 2023
- Full Text
- View/download PDF